DelveInsight’s, “Exosomes Pipeline Insight, 2023” report provides comprehensive insights about 60+ companies and 110+ pipeline drugs in the Exosomes pipeline landscape. It covers the Exosomes pipeline drug profiles, including Exosomes clinical trials and nonclinical stage products. It also covers the Exosomes pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Exosomes pipeline products in this space.
In the Exosomes pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Exosomes clinical trials studies, Exosomes NDA approvals (if any), and product development activities comprising the technology, Exosomes collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Key takeaways from the Exosomes Pipeline Insight Report
- Over 60+ Exosomes companies are evaluating 110+ Exosomes pipeline therapies in various stages of development, and their anticipated acceptance in the Exosomes market would significantly increase market revenue.
- The leading Exosomes Companies includes Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group, Aegle Therapeutics, Organicell Regenerative Medicine, Codiak BioSciences, Cellular Biomedicine Group, StemXO Therapeutics, Cells for Cells, RION, Cell Care Therapeutics, Novadip, Ilias, Ilias, ReNeuron, Evora Bioscineces, Coya Therapeutics, ShiftBio Inc., Exostemtech, Celularity, Azymus Therapeutics, and others.
- Promising Exosomes Pipeline Therapies includes ExoIntelliScore Prostate, MSCs-derived Exosomes, Test: ExoDx Prostate(IntelliScore), Zofin, ExoFlo, Intravenous normal saline, Olmutinib, and others.
- The Exosomes companies and academics are working to assess challenges and seek opportunities that could influence Exosomes R&D. The Exosomes pipeline therapies under development are focused on novel approaches to treat/improve Exosomes.
To explore more information on the latest breakthroughs in the Exosomes Pipeline treatment landscape of the report, click here @ Exosomes Pipeline Outlook
Exosomes Overview
An exosome is a type of extracellular vesicle (EV), a family of nanometer-scale, biomolecule-filled, lipid-wrapped packages released by most cells. Exosomes are released from cells upon fusion of an intermediate endocytic compartment, the multivesicular body (MVB), with the plasma membrane. This liberates intraluminal vesicles (ILVs) into the extracellular milieu and the vesicles thereby released are what we know as exosomes. They are found in mostly all biological fluids, such as breast milk, blood, urine, and semen. After secretion, these are taken up by distant cells, affecting cell function and behavior. Exosomes play a role in cell–cell communication and the transmission of disease states and explored as a means of drug discovery. Exosomes are generated in a process that involves double invagination of the plasma membrane and the formation of intracellular multivesicular bodies (MVBs) containing intraluminal vesicles (ILVs).
Latest Breakthroughs or News of the Exosomes Treatment Landscape
- In 2022, Bio-Techne and Thermo Fisher Scientific came to an agreement for the creation of the ExoTRU kidney transplant rejection test. Information about the health of the allografts that can be used in clinical settings will be provided by this test.
- In 2020, Lonza purchased Codiak Biosciences’ exosome facility. The latter retains its exosome drug-loading technologies and therapeutic candidate pipeline.
For further information, refer to the detailed Exosomes Unmet Needs, Exosomes Market Drivers, and Exosomes Market Barriers, click here for Exosomes Ongoing Clinical Trial Analysis
Exosomes Emerging Drugs Profile
CAP-1002: Capricor
Capricor’s (CAP-1002) is based on cardiosphere-derived cells, or CDCs, a cardiac-derived cell therapy that was first identified in the academic laboratory of Capricor’s scientific founder, Dr. Eduardo Marbán. CDCs have been the subject of over 100 peer-reviewed scientific publications and have been administered to over 200 human subjects across several clinical trials. CAP-1002 contains cardiosphere-derived cells, a type of heart cell progenitor, or precursor cell, that secretes tiny vesicles called exosomes. These exosomes then modulate the activity of the immune system and stimulate cellular regeneration. It is being investigated for its potential to modify the immune system’s activity to encourage cellular regeneration. The cells function by releasing exosomes that are taken up largely by macrophages and T-cells and begin a cycle of repair. Currently the drug is in Phase III stage of clinical trial evaluation for the treatment of Duchenne Muscular Dystrophy.
Progenza: Regeneus
Progenza is an off-the-shelf allogeneic stem cell product with the first targeted treatment being for knee osteoarthritis. The product is produced from mesenchymal stem cells (MSCs) from adipose (fat) tissue from a healthy donor who has been extensively screened. Progenza includes secretions from donor MSCs that improves viability and functionality of the cells after freezing.
Adipose tissue is readily available from donors in large quantities and has significantly higher MSCs per gram of tissue than other tissue sources such as bone marrow or cord tissue. Adipose derived MSCs also have the added advantage of showing greater capacity for expansion than MSCs from other tissue types. Currently, the drug is in Phase II stage of Clinical trial evaluation for the treatment of Osteoarthritis.
AGLE 102: Aegle Therapeutics
AGLE 102 is an allogeneic derived extracellular vesicle (EV) product derived from normal donor mesenchymal stem cells (MSCs). AGLE-102 is a composite of mesenchymal stem cell-derived extracellular vesicles that deliver proteins, genetic material and regenerative healing factors to diseased and damaged tissue.It is being developed by Aegle Therapeutics for Dystrophic Epidermolysis Bullosa.
Zofin: Organicell Regenerative Medicine
Zofin is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs, without the addition or combination of any other substance or diluent. This product contains over 300 growth factors, cytokines, chemokines, and 102 unique microRNAs as well as other exosomes/nanoparticles derived from perinatal tissues. Zofin is currently being tested in a phase I/II randomized, double blinded, placebo trial to evaluate the safety and potential efficacy of intravenous infusion of Zofin for the treatment of moderate to SARS related to COVID-19 infection vs placebo.
Exo-101: Exogenus Therapeutics
Exogenus developed a product Exo–101, based on vesicles released by mononuclear cells from umbilical cord blood, which shows promise for regenerative medicine (namely healing of chronic wounds) and inflammatory diseases. Known for their capacity to travel long distances within the body and support cellular communication, these nano-sized vesicles are also thought to be safer than cellular therapies, while maintaining similar efficacy. Due to its immunomodulatory properties, Exo-101 is being explored for inflammatory skin diseases, such as psoriasis. The combination of pro-regenerative and anti-inflammatory potential of Exo-101 may benefit patients with inflammatory lung diseases, including COVID-19-related respiratory complications. Exo-101 has been shown to accelerate the healing of chronic wounds.
COYA 201: Coya Therapeutics
COYA 201 product candidate utilizes Treg-derived exosome therapeutic modality. For COYA 201, the company is currently completing animal model studies and will conduct pharmacology, toxicology and other IND-enabling studies to support the initiation of clinical trials in neurodegenerative, autoimmune and metabolic diseases.
Exosomes Pipeline Therapeutics Assessment
There are approx. 60+ key companies which are developing the therapies for Exosomes. The companies which have their Exosomes drug candidates in the most advanced stage, i.e. phase III include, Capricor.
Request a sample and discover the recent advances in Exosomes Ongoing Clinical Trial Analysis and Medications, click here @ Exosomes Treatment Landscape
Scope of the Exosomes Pipeline Insight Report
- Coverage- Global
- Exosomes Companies- Capricor Therapeutics, Direct Biologics, Regeneus, OBCTCD24, AVEM HealthCare, Cellular Biomedicine Group, Aegle Therapeutics, Organicell Regenerative Medicine, Codiak BioSciences, Cellular Biomedicine Group, StemXO Therapeutics, Cells for Cells, RION, Cell Care Therapeutics, Novadip, Ilias, Ilias, ReNeuron, Evora Bioscineces, Coya Therapeutics, ShiftBio Inc., Exostemtech, Celularity, Azymus Therapeutics, and others.
- Exosomes Pipeline Therapies- ExoIntelliScore Prostate, MSCs-derived Exosomes, Test: ExoDx Prostate(IntelliScore), Zofin, ExoFlo, Intravenous normal saline, Olmutinib, and others.
- Exosomes Pipeline Segmentation: Phases, Mechanism of Action, Route of Administration, Product Type
Dive deep into rich insights for drugs for Exosomes Market Drivers and H Exosomes Market Barriers, click here @ Exosomes Unmet Needs and Analyst Views
Table of Content
- Introduction
- Executive Summary
- Exosomes: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Exosomes– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- CAP-1002: Capricor
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Progenza: Regeneus
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- StemXO Endosome Therapy: Stem XO Therapeutics
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Exo-101: Exogenus Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Exosome – Collaborations Assessment- Licensing / Partnering / Funding
- Exosomes- Unmet Needs
- Exosomes- Market Drivers and Barriers
- Appendix
Got Queries? Find out the related information on Exosomes Mergers and acquisitions, Exosomes Licensing Activities @ Exosomes Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services